Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery
- Status
- COMPLETED
- Phase
- PHASE2
PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer
- Status
- UNKNOWN
- Phase
- PHASE1
Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC
- Status
- COMPLETED
- Phase
- PHASE2
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC
- Status
- COMPLETED
- Phase
- PHASE1
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
- Status
- TERMINATED
- Phase
- PHASE1
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Surgical Nivolumab And Ipilimumab For Recurrent GBM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- NA
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE1
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Nivolumab+Ipilimumab+RT in MSS mCRC
- Status
- UNKNOWN
- Phase
- PHASE2
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1